Judge Rodney Sippel's October 8, 2013 Order Rescheduling First NuvaRing MDL Trial
The trial date for the Prather case has been reset and will now be April 7, 2014.
The Prather v. Organon case, 4:08 CV 558 RWS, which had been set to start trial in October 2013 has been rescheduled. The Prather NuvaRing trial will now be held on January 27, 2014, according to this latest Order by Judge Sippel.
From the conclusion of this same July 2013 Order:
IT IS FURTHER ORDERED that the parties are ordered to maintain regular and frequent contact with the mediator who will report the status of any negotiations to the Court.
The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business day. Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit. We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you. Go to Form
Marie Claire magazine, June 2011 -- By Laura Beil
More than 1500 women have filed NuvaRing lawsuits, now, claiming it has caused potentially life-threatening blood clots resulting in them developing a deep vein thrombosis (DVT), pulmonary embolism (PE), or stroke.
Includes interview with attorney Tom Lamb.
Read the full article here: Birth Control Health Risks - Is the NuvaRing Dangerous? - Marie Claire
My Articles About NuvaRing
In Addition, The New Package Insert No Longer States It Is Unknown If NuvaRing Has A Different Blood Clot (VTE) Risk Than Some Birth Control Pills
SUMMARY: In October 2013 the FDA approved some revisions to the NuvaRing label that can be found in the "Warnings and Precautions" section, specifically at this part, "Thromboembolic Disorders and Other Vascular Problems".
The two competing medical studies are:
• 1. Dinger, J et. al., Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstetrics & Gynecology 2013; 122(4): 800-808.
• 2. Sidney, S. et. al., Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013; 87: 93–100.
We will continue to monitor the safety profile of NuvaRing as well as the related products liability litigation involving more than 1500 personal injury and wrongful death cases.
Earlier NuvaRing articles by Tom Lamb on the Drug Injury Watch blog:
Drug Injury Watch: Merck Funded Study Says There Is No Blood Clot Risk With NuvaRing, While BMJ Medical Journal Article Reports A 90% Increased Risk
More About NuvaRing At Our DrugInjuryLaw.com Web Site
Visit the NuvaRing Information page at our Drug Injury Law web site for up-to-the-date developments regarding personal injury and wrongful death lawsuits that involve NuvaRing.
The Law Offices of Thomas J. Lamb, P.A. is handling personal injury and wrongful death lawsuits against the drug company when any of these medical conditions developed while using NuvaRing:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)